Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis

INTRODUCTION: Trastuzumab, as the gold standard for HER2-positive BC treatment, was the first-line HER2 targeted drug. However, some studies reported patients benefited more from lapatinib and lapatinib plus trastuzumab therapy than standard trastuzumab therapy. This study presents an update of a sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Ye, Liu, Xumei, Cai, Yi, Li, Wenyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Systematic Review Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738024/
https://www.ncbi.nlm.nih.gov/pubmed/36496473
http://dx.doi.org/10.1186/s13643-022-02134-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738024/
https://www.ncbi.nlm.nih.gov/pubmed/36496473
http://dx.doi.org/10.1186/s13643-022-02134-9

Ejemplares similares